T1	PROC 46 73	Estudio sin enmascaramiento
T2	Neg_cue 54 57	sin
T3	Negated 58 73	enmascaramiento
T4	Date 74 87	a largo plazo
T5	PROC 93 127	evaluar la seguridad y la eficacia
T6	CHEM 131 143	donidalorsén
T7	PROC 149 173	tratamiento profiláctico
#1	AnnotatorNotes T7	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T8	DISO 178 200	angioedema hereditario
#2	AnnotatorNotes T8	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T9	DISO 202 205	AEH
#3	AnnotatorNotes T9	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T10	DISO 230 249	Enfermedad genética
#4	AnnotatorNotes T10	C0019247; Hereditary Diseases; Disease or Syndrome
T11	DISO 284 317	edemas subcutáneos y/o submucosos
T12	Duration 318 330	transitorios
T13	DISO 361 370	hinchazón
#5	AnnotatorNotes T13	C0038999; Swelling; Finding
T14	DISO 375 390	dolor abdominal
#6	AnnotatorNotes T14	C0000737; Abdominal Pain; Sign or Symptom
T15	DISO 417 439	angioedema hereditario
#7	AnnotatorNotes T15	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T16	DISO 441 444	AEH
#8	AnnotatorNotes T16	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T17	LIVB 479 492	participantes
T18	LIVB 519 533	representantes
#9	AnnotatorNotes T18	C0600419; Patient Agent; Group | C1708966; Medical Equipment Company Technician or Representative; Professional or Occupational Group
T19	LIVB 568 588	padre(s)/tutor legal
T20	PROC 627 651	consentimiento informado
#10	AnnotatorNotes T20	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T21	PROC 653 656	ICF
T22	LIVB 688 701	participantes
T23	CHEM 752 775	medicamento(s) agudo(s)
T24	CHEM 785 819	concentrado de C1-INH recombinante
T25	CHEM 822 840	derivado de plasma
T26	CHEM 846 893	antagonista del receptor de bradicinina (BK) 2)
T27	PROC 899 905	tratar
T28	DISO 910 931	ataques de angioedema
T29	LIVB 937 950	participantes
T30	PROC 1035 1088	estudio de índice aleatorizado controlado con placebo
T31	Date 1096 1108	la semana 25
T32	LIVB 1111 1124	participantes
T33	PROC 1188 1197	protocolo
#11	AnnotatorNotes T33	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T34	LIVB 1251 1264	Participantes
T35	Neg_cue 1273 1275	no
T36	Negated 1276 1303	previamente en donidalorsen
T37	LIVB 1322 1335	participantes
T38	Age 1348 1357	≥ 12 años
T39	PROC 1376 1400	consentimiento informado
#12	AnnotatorNotes T39	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T40	LIVB 1447 1460	participantes
T41	PROC 1476 1487	diagnóstico
#13	AnnotatorNotes T41	C0011900; Diagnosis; Diagnostic Procedure
T42	DISO 1503 1508	HAE-1
T43	DISO 1509 1514	HAE-2
T44	LIVB 1522 1535	participantes
T45	Dose 1551 1568	una dosis estable
T46	Duration 1569 1582	(≥ 12 semanas
T47	PROC 1587 1611	tratamiento profiláctico
#14	AnnotatorNotes T47	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T48	CHEM 1616 1627	lanadelumab
T49	CHEM 1630 1642	berotralstat
T50	CHEM 1645 1675	inhibidor de la esterasa SC C1
T51	CHEM 1844 1854	medicación
#15	AnnotatorNotes T51	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T52	LIVB 1855 1868	Participantes
T53	PROC 1880 1903	Diagnóstico concurrente
T54	DISO 1930 1940	angioedema
#16	AnnotatorNotes T54	C0002994; Angioedema; Pathologic Function
T55	DISO 1965 1996	angioedema idiopático adquirido
T56	DISO 1999 2002	AEH
#17	AnnotatorNotes T56	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T58	DISO 2044 2056	AEH tipo III
T59	CHEM 2092 2102	andrógenos
#18	AnnotatorNotes T59	C0002844; Androgens; Hormone · Pharmacologic Substance
T60	PROC 2119 2129	profilaxis
#19	AnnotatorNotes T60	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T61	CHEM 2134 2151	ácido tranexámico
#20	AnnotatorNotes T61	C0040613; tranexamic acid; Organic Chemical · Pharmacologic Substance
T62	PROC 2157 2165	prevenir
#21	AnnotatorNotes T62	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T63	DISO 2166 2187	ataques de angioedema
T64	DISO 2198 2209	anormalidad
#22	AnnotatorNotes T64	C1704258; Abnormality; Finding
T65	PROC 2244 2279	valores de laboratorio de detección
T66	DISO 2283 2300	Neoplasia maligna
#23	AnnotatorNotes T66	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T67	Duration 2311 2321	los 5 años
T68	PROC 2339 2348	detección
#24	AnnotatorNotes T68	C1511790; Detection; Therapeutic or Preventive Procedure
T69	Neg_cue 2350 2364	a excepción de
T70	DISO 2369 2397	cánceres de piel no melanoma
#25	AnnotatorNotes T70	C0699893; Skin carcinoma; Neoplastic Process
T71	Negated 2369 2397	cánceres de piel no melanoma
T72	DISO 2402 2437	carcinoma in situ de cuello uterino
T73	Negated 2402 2437	carcinoma in situ de cuello uterino
T74	DISO 2442 2474	carcinoma ductal de mama in situ
T75	Negated 2442 2474	carcinoma ductal de mama in situ
T76	DISO 2480 2501	carcinoma de próstata
#26	AnnotatorNotes T76	C0600139; Prostate carcinoma; Neoplastic Process
T77	Negated 2480 2501	carcinoma de próstata
T78	PROC 2527 2534	tratado
T79	DISO 2549 2566	Hipersensibilidad
#27	AnnotatorNotes T79	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T80	CHEM 2570 2586	principio activo
T81	CHEM 2588 2600	donidalorsen
T82	CHEM 2620 2631	excipientes
#28	AnnotatorNotes T82	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T83	PROC 2635 2646	Tratamiento
#29	AnnotatorNotes T83	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T84	CHEM 2656 2680	fármaco en investigación
T85	Neg_cue 2682 2684	no
T86	CHEM 2685 2700	oligonucleótido
#30	AnnotatorNotes T86	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T87	Negated 2685 2700	oligonucleótido
T88	CHEM 2704 2720	agente biológico
#31	AnnotatorNotes T88	C0005515; Biological Factors; Biologically Active Substance
T89	Duration 2736 2741	1 mes
T90	Duration 2763 2774	5 semividas
T91	CHEM 2779 2802	agente en investigación
T92	Date 2838 2846	reciente
T93	DISO 2849 2881	abuso actual de drogas o alcohol
T94	Date 2855 2861	actual
T95	CHEM 2921 2933	donidalorsen
T96	CHEM 2979 2991	medicamentos
#32	AnnotatorNotes T96	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T97	CHEM 2993 3046	Inhibidores de la enzima convertidora de angiotensina
#33	AnnotatorNotes T97	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T98	CHEM 3048 3051	ECA
#34	AnnotatorNotes T98	C0022709; Peptidyl-Dipeptidase A; Amino Acid, Peptide, or Protein · Enzyme · Immunologic Factor
T99	CHEM 3065 3076	medicamento
#35	AnnotatorNotes T99	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T100	CHEM 3090 3099	estrógeno
#36	AnnotatorNotes T100	C0014939; estrogens; Hormone · Organic Chemical · Pharmacologic Substance
T101	PHYS 3104 3113	absorción
T102	CHEM 3124 3140	Oligonucleótidos
#37	AnnotatorNotes T102	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T103	CHEM 3154 3197	ácido ribonucleico de interferencia pequeño
T104	CHEM 3199 3204	siRNA
T105	Duration 3217 3228	los 4 meses
T106	Dose 3270 3285	una dosis única
T107	Duration 3299 3311	los 12 meses
T108	Dose 3356 3371	dosis múltiples
T109	Neg_cue 3388 3390	no
T110	CHEM 3407 3414	vacunas
#38	AnnotatorNotes T110	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T111	Negated 3407 3414	vacunas
T112	CHEM 2007 2013	C1-INH
T113	Route 1670 1672	SC